Infervision vs Qure.ai
Infervision suits a radiology group reading chest CT that wants nodule follow-up with volume doubling time, and a thoracic service that wants 3D surgical planning from InferOperate. InferRead Lung CT.AI was cleared in July 2020 and again in May 2025. Qure.ai suits a hospital that wants head CT triage and lung nodule CT next to chest X-ray, with qER first cleared in June 2020 and qCT Lung in September 2026.
TB screening is where the two reach the same setting. An independent Lusaka evaluation of InferRead DR Chest reported 90.3% sensitivity at 39.2% specificity at cut-off 0.12. A separate 12-product evaluation reported qXR v3 at 95.5% sensitivity and 48.7% specificity at one threshold. Those are two studies with different designs.
On chest X-ray the records differ in what they name. Qure.ai's include qXR-LN (K231805, December 2023) for nodules on adult frontal chest radiographs and qXR-PTX-PE (K230899, August 2023) for pneumothorax and effusion triage. Infervision's six name InferRead Lung CT.AI, InferRead CT Stroke.AI, InferOperate Suite and InferCare RECIST. For a community hospital radiology department buying chest X-ray AI, Infervision loses.
Radiology · Reviewed November 2, 2026
Infervision
by Infervision · founded 2016
AI for CT lung nodules, CT stroke, surgical planning and RECIST follow-up, with FDA clearances for these CT products.
Qure.ai
by Qure.ai
AI for chest X-ray (qXR), head CT (qER) and lung nodule CT, with TB screening. The homepage cites sites across 107 countries.
When to pick each one
Infervision
- Lung CT nodule follow-up with volume doubling time
- 3D surgical planning and RECIST follow-up cleared
Qure.ai
- Chest X-ray nodule detection, K231805 December 2023
- Ten FDA 510(k) clearances across chest, head CT and lung CT
Score
Each row shows points earned of points available under the published rubric.
Infervision
57of 100
Qure.ai
50of 100
| Dimension | Infervision | Qure.ai | Difference |
|---|---|---|---|
| FDA clearance | 18 / 18 | 18 / 18 | 0 |
| HIPAA / SOC2 / BAA | 0 / 10 | 0 / 10 | 0 |
| EHR integrations (count) | 0 / 4.2 | 0 / 4.2 | 0 |
| Top-3 EHR coverage (Epic / Oracle / Athena) | 0 / 2.4 | 0 / 2.4 | 0 |
| Peer-reviewed papers | 12.7 / 18.2 | 12.7 / 18.2 | 0 |
| RCT / meta-analysis / systematic review | 0 / 7.8 | 0 / 7.8 | 0 |
| Funding & adoption signal | 8.4 / 12 | 8.4 / 12 | 0 |
| Pricing transparency | 2.5 / 5 | 2.5 / 5 | 0 |
| Years in market | 6 / 6 | 0 / 6 | +6 |
Scroll horizontally to see every column.
Pricing
Infervision
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. |
Qure.ai
| Tier | Monthly | Annual | Notes |
|---|---|---|---|
| Enterprise | n/a | n/a | No public price. Grant funding is not stated on Qure pages. |
Evidence
Infervision
FDA decisions
K260973 (opens in new tab)510(k)2026-07-07
InferOperate Suite
K252261 (opens in new tab)510(k)2026-03-13
InferCare RECIST
K250237 (opens in new tab)510(k)2025-09-15
InferOperate Suite
K240554 (opens in new tab)510(k)2025-05-16
InferRead Lung CT.AI
K211179 (opens in new tab)510(k)2021-08-12
InferRead CT Stroke.AI
Show 1 more
K192880 (opens in new tab)510(k)2020-07-02
InferRead Lung CT.AI
Peer-reviewed
4 PubMed records name Infervision.
- Spatial classification of clinical T1a-bN0 non-small cell lung cancer in superior segment based on three-dimensional reconstruction: optimizing surgical margin and operative strategy. (opens in new tab)
- AI-assisted clinico-quantitative imaging nomogram for preoperative malignancy risk in solid and part-solid pulmonary nodules ≤ 3 cm: development and internal validation. (opens in new tab)
- Impact of dose reduction and iterative reconstruction algorithm on the detectability of pulmonary nodules by artificial intelligence. (opens in new tab)
Qure.ai
FDA decisions
K261517 (opens in new tab)510(k)2026-09-14
qCT Lung v1.0
K251934 (opens in new tab)510(k)2026-01-16
qXR-Detect
K251610 (opens in new tab)510(k)2025-09-08
qER-CTA v1.0
K240740 (opens in new tab)510(k)2024-08-16
qCT LN Quant
K231805 (opens in new tab)510(k)2023-12-22
qXR-LN
Show 5 more
K231149 (opens in new tab)510(k)2023-09-22
qXR-CTR
K230899 (opens in new tab)510(k)2023-08-22
qXR-PTX-PE
K212690 (opens in new tab)510(k)2021-12-21
qXR-BT
K211222 (opens in new tab)510(k)2021-07-30
qER-Quant
K200921 (opens in new tab)510(k)2020-06-17
qER
Peer-reviewed
4 PubMed records name Qure.ai.
- Radiograph accelerated detection and identification of cancer in the lung (RADICAL): a mixed methods study to assess the clinical effectiveness and acceptability of Qure.ai artificial intelligence software to prioritise chest X-ray (CXR) interpretation. (opens in new tab)
- Revolutionizing Healthcare: Qure.AI's Innovations in Medical Diagnosis and Treatment. (opens in new tab)
- A Case Series From a Multicentric Study: Can Artificial Intelligence (AI)-Enabled Chest X-Ray Assist in the Incidental Detection of Early-Stage Lung Cancers? (opens in new tab)
Compliance and integrations
Documented from each vendor’s own pages.
| Spec | Infervision | Qure.ai |
|---|---|---|
| Free tier | ||
| HIPAA | ||
| SOC 2 Type II | ||
| EHR integrations | Not specified | Not specified |
| Founded | 2016 | n/a |
| HQ | n/a | IN |
Scroll horizontally to see both columns.
Common questions
Open the full radiology comparison
Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.